Humana price target lowered to $252 from $312 at Guggenheim

Guggenheim lowered the firm’s price target on Humana (HUM) to $252 from $312 and keeps a Buy rating on the shares. Q4 MLR upside was overshadowed by 2026’s outsized 25% membership growth, fueling an incremental roughly $1B net Stars headwind, the analyst tells investors. The firm, which expects further debates on how Humana will choose to navigate the 2027 rate environment, says it chooses to take “a prudent view” on 2027 EPS generation, resulting in its lowered target.